Type 2 diabetes

E Ahmad, S Lim, R Lamptey, DR Webb, MJ Davies - The Lancet, 2022 - thelancet.com
Type 2 diabetes accounts for nearly 90% of the approximately 537 million cases of diabetes
worldwide. The number affected is increasing rapidly with alarming trends in children and …

[HTML][HTML] Lipid droplet biogenesis and functions in health and disease

A Zadoorian, X Du, H Yang - Nature Reviews Endocrinology, 2023 - nature.com
Ubiquitous yet unique, lipid droplets are intracellular organelles that are increasingly being
recognized for their versatility beyond energy storage. Advances uncovering the intricacies …

[HTML][HTML] Lipogenesis inhibitors: therapeutic opportunities and challenges

B Batchuluun, SL Pinkosky, GR Steinberg - Nature Reviews Drug …, 2022 - nature.com
Fatty acids are essential for survival, acting as bioenergetic substrates, structural
components and signalling molecules. Given their vital role, cells have evolved mechanisms …

Recompensation in cirrhosis: unravelling the evolving natural history of nonalcoholic fatty liver disease

G Feng, L Valenti, VWS Wong, YM Fouad… - Nature Reviews …, 2024 - nature.com
Recompensation has gained increasing attention in the field of cirrhosis, particularly in
chronic liver disease with a definite aetiology. The current global prevalence of obesity and …

Association of bariatric surgery with major adverse liver and cardiovascular outcomes in patients with biopsy-proven nonalcoholic steatohepatitis

A Aminian, A Al-Kurd, R Wilson, J Bena, H Fayazzadeh… - Jama, 2021 - jamanetwork.com
Importance No therapy has been shown to reduce the risk of serious adverse outcomes in
patients with nonalcoholic steatohepatitis (NASH). Objective To investigate the long-term …

The associations between modifiable risk factors and nonalcoholic fatty liver disease: A comprehensive Mendelian randomization study

J Xie, H Huang, Z Liu, Y Li, C Yu, L Xu, C Xu - Hepatology, 2023 - journals.lww.com
Conclusions: Genetically predicted alcohol frequency, elevated serum liver enzymes, poor
physical condition, obesity traits, T2DM, and hypertension were associated with an …

Glucagon-like peptide-1 receptor-based therapeutics for metabolic liver disease

JM Yabut, DJ Drucker - Endocrine Reviews, 2023 - academic.oup.com
Abstract Glucagon-like peptide-1 (GLP-1) controls islet hormone secretion, gut motility, and
body weight, supporting development of GLP-1 receptor agonists (GLP-1RA) for the …

Role of turmeric and curcumin in prevention and treatment of chronic diseases: Lessons learned from clinical trials

AB Kunnumakkara, M Hegde, D Parama… - ACS Pharmacology & …, 2023 - ACS Publications
Turmeric (Curcuma longa) has been used for thousands of years for the prevention and
treatment of various chronic diseases. Curcumin is just one of> 200 ingredients in turmeric …

[HTML][HTML] En masse organoid phenotyping informs metabolic-associated genetic susceptibility to NASH

M Kimura, T Iguchi, K Iwasawa, A Dunn, WL Thompson… - Cell, 2022 - cell.com
Genotype-phenotype associations for common diseases are often compounded by
pleiotropy and metabolic state. Here, we devised a pooled human organoid-panel of …

[HTML][HTML] The bidirectional immune crosstalk in metabolic dysfunction-associated steatotic liver disease

K Sawada, H Chung, S Softic, ME Moreno-Fernandez… - Cell Metabolism, 2023 - cell.com
Metabolic dysfunction-associated steatotic liver disease (MASLD) is an unabated risk factor
for end-stage liver diseases with no available therapies. Dysregulated immune responses …